JCI's 2017 Impact Factor: 13.251

The Journal of Clinical Investigation’s 2017 Impact Factor is 13.251. This metric, published in Journal Citation Reports (JCR), places the JCI among the top journals in the JCR category of Medicine, Research & Experimental. The JCI’s 5-year Impact Factor is 14.434.

How the Impact Factor is calculated. The Impact Factor is a ratio calculated as the number of citations in a given year to articles published in the two previous years divided by the number of articles published in those years. Thus, the most recent Impact Factor represents citations in 2017 to articles published in 2015 and 2016; the 5-year Impact Factor represents citations in 2017 to articles published in 2012–2016.

Use of the Impact Factor. Because the Impact Factor is based on citations to many articles within a journal, the metric should be interpreted as an indicator of a journal’s overall relevance to researchers and not as an indicator of the relevance or quality of any single article or of the work performed by researchers represented in a journal.

Selected highly cited articles in the JCI

Citation data are from Web of Science as of July 2018.

CD19 CAR-T cells of defined CD4⁺:CD8⁺ composition in adult B cell ALL patients
Cameron J. Turtle, … Stanley R. Riddell, David G. Maloney
Oncology Times cited: 122

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky, … Michel Sadelain, Prasad S. Adusumilli
Oncology Times cited: 65

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Adil I. Daud, … Matthew F. Krummel, Michael D. Rosenblum
Oncology Times cited: 50

Metabolic programming and PDHK1 control CD4⁺ T cell subsets and inflammation
Valerie A. Gerriets, … Mari L. Shinohara, Jeffrey C. Rathmell
Immunology Times cited: 47

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Changtao Jiang, … Andrew D. Patterson, Frank J. Gonzalez
Hepatology Times cited: 47

Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird, … Janet D. Siliciano, Robert F. Siliciano
AIDS/HIV Times cited: 40

The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Peter Huebener, … Daniel J. Antoine, Robert F. Schwabe
Immunology Times cited: 39

MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis
Mireille Ouimet, … P’ng Loke, Kathryn J. Moore
Vascular biology Times cited: 39

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
David J. DiLillo, … Patrick C. Wilson, Jeffrey V. Ravetch
Immunology Times cited: 35

Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways
Ivan G. Gomez, … Nelson Chau, Jeremy S. Duffield
Nephrology Times cited: 33